Key result
PASCAL system offers effective transcatheter edge-to-edge repair for patients with mitral regurgitation.
Why the study?
The PASCAL transcatheter valve repair system is a novel treatment with growing evidence supporting its safety, efficacy, and durability for mitral valve leaflet repair.
The PASCAL transcatheter valve repair system is an FDA-approved treatment option for mitral regurgitation, suitable for a broad range of straightforward and complex anatomies.
May support PASCAL use across varied mitral anatomies; leaves open need for comparative trials.
The PASCAL transcatheter valve repair system, with the PASCAL and PASCAL Ace implants, is a novel treatment option with design features that are well suited for a broad range of straightforward and complex anatomies. Growing commercial and investigational experience support the safety, efficacy, and durability of the PASCAL repair system for transcatheter mitral valve leaflet repair. With the recent completion of the CLASP IID trial along with US Food and Drug Administration approval, PASCAL is now an essential treatment option for MR.
No takes yet. Share an insight, caveat, or question.
Whisenant et al. (2023) conducted a review in Mitral regurgitation. PASCAL transcatheter valve repair system was evaluated. The PASCAL transcatheter valve repair system is an essential and effective treatment option for transcatheter mitral valve leaflet repair in patients with mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: